LM11A-31 structure
|
Common Name | LM11A-31 | ||
|---|---|---|---|---|
| CAS Number | 102562-74-3 | Molecular Weight | 279.807 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C12H25N3O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LM11A-31An orally available, brain penetrant p75NTR ligand that blocks p75-mediated cell death, also increases proliferation and survival of hippocampal neural progenitors; shows no effect on nerve growth factor (NGF) binding to TrkA; prevents and reverses atrophy of cholinergic neurites, as well as reversing AD pathologies in mid- to late-stage AD mice models. Alzheimer Disease Phase 2 Clinical |
| Name | N-[2-(4-Morpholinyl)ethyl]-L-isoleucinamide hydrochloride (1:1) |
|---|---|
| Synonym | More Synonyms |
| Description | An orally available, brain penetrant p75NTR ligand that blocks p75-mediated cell death, also increases proliferation and survival of hippocampal neural progenitors; shows no effect on nerve growth factor (NGF) binding to TrkA; prevents and reverses atrophy of cholinergic neurites, as well as reversing AD pathologies in mid- to late-stage AD mice models. Alzheimer Disease Phase 2 Clinical |
|---|---|
| References | References 1. Massa SM, et al. J Neurosci. 2006 May 17;26(20):5288-300. 2. Meeker RB, et al. J Neuroimmune Pharmacol. 2012 Jun;7(2):388-400. 3. Simmons DA, et al. PLoS One. 2014 Aug 25;9(8):e102136. 4. Meeker RB, et al. Exp Neurol. 2016 Jan;275 Pt 1:182-98. View Related Products by Target Trk Receptor Alzheimer Disease |
| Molecular Formula | C12H25N3O2 |
|---|---|
| Molecular Weight | 279.807 |
| Exact Mass | 279.171356 |
| N-[2-(4-Morpholinyl)ethyl]-L-isoleucinamide hydrochloride (1:1) |
| Pentanamide, 2-amino-3-methyl-N-[2-(4-morpholinyl)ethyl]-, (2S,3S)-, hydrochloride (1:1) |